A pivotal phase III study of Murepavadin for the treatment of patients with nosocomial pneumonia (Ventilator-associated and hospital-acquired pneumonia)

Trial Profile

A pivotal phase III study of Murepavadin for the treatment of patients with nosocomial pneumonia (Ventilator-associated and hospital-acquired pneumonia)

Planning
Phase of Trial: Phase III

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Murepavadin (Primary)
  • Indications Nosocomial pneumonia
  • Focus Registrational; Therapeutic Use
  • Sponsors Polyphor
  • Most Recent Events

    • 16 Nov 2017 According to a Polyphor media release, Professor Stuart Elborn, Professor of respiratory medicine at the Royal Brompton Hospital is the principal investigator of the study
    • 27 May 2017 New trial record
    • 19 May 2017 According to a Polyphor media release, the company is working in collaboration with its investigators to finalize the detailed protocol design and plans to recruit the first patient by first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top